The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Abstract

The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention. 

For individuals at increased risk of ovarian carcinoma, risk-reducing bilateral salpingo-oophorectomy (RRSO) is highly effective, but uptake at the recommended age is suboptimal, likely due to concerns about premature menopause. 

Mounting evidence suggests that many “ovarian” cancers originate in the fallopian tube, making bilateral salpingectomy with delayed oophorectomy an attractive, but as of yet, unproven option for risk-reduction in those who decline RRSO. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 
PodcastThe Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
By Paul Goldberg and Claire Marie Porter
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account